Literature DB >> 765352

Hyperprolactinemic anovulatory syndrome.

H G Bohnet, H G Dahlén, W Wuttke, H P Schneider.   

Abstract

The functional status of the hypothalamo-pituitary-gonadal axis was investigated in 127 women with anovulatory disease. Radioimmunoassayable circulating LH, FSH, and prolactin concentrations were measured. An attempt was made to localize the functional lesion by utilizing the following criteria: 1. Hypothalamic function: a) clomiphene test based upon hormonal parameters; b) recording of the pulsatile LH fluctuation (spiking) and of basal FSH. 2. Pituitary function: determination of the gonadotropin reserve by means of a standardized LRH test. 3. Ovarian function: a) measurement of plasma E2 and progesterone levels by RIA; b) gestagen bleeding test. All patients had amenorrhea of up to 14 years duration. A total of 17 hyperprolactinemic patients (13.4%) was found. Eight of these patients never experienced galatorrhea, in 7 only transient galactorrhea was reported, and in 2 cases galactorrhea persisted. All hyperprolactinemic patients were found to be clomiphene non-responders as well as nonspikers. The pituitary LH reserve varied from practically none to normal. Baseline LH was low whereas that of FSH was normal. In accordance with this observation E2 levels, with two exceptions, were found to be in the lower range of normal female concentrations. Thus, all but two patients exhibited gestagen withdrawal bleeding. In conclusion, the hyperprolactinemic anvoluatory syndrome is not necessarily associated with galactorrhea. In all cases of amenorrhea syndromes with or without galactorrhea, hyperprolactinemia should be excluded as it is very often associated with anovulation. The hyperprolactinemic anovulatory syndrome includes the following features: 1. gestagen withdrawal bleeding. 2. subnormal to normal E2 levels. 3. clomiphene nonresponsiveness. 4. LH-hypogonadotropism. 5. lack of LH secretory episodes. 6. FSH-normogonadotropism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 765352     DOI: 10.1210/jcem-42-1-132

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

1.  Hyperprolactinemia in anovulatory women. Incidence and endocrine features.

Authors:  A S Wolf; K Musch; C Lauritzen
Journal:  J Endocrinol Invest       Date:  1979 Jan-Mar       Impact factor: 4.256

Review 2.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

3.  Disorders of prolactin secretion.

Authors:  M O Thorner
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1976

4.  Anovulation and ovulation induction.

Authors:  I Katsikis; M Kita; A Karkanaki; N Prapas; D Panidis
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

5.  Prolactin and human reproduction.

Authors:  G Tolis; H G Friesen
Journal:  Can Med Assoc J       Date:  1976-10-23       Impact factor: 8.262

6.  Hypothalamic-pituitary-ovarian function in hyperprolactinemic women.

Authors:  P Travaglini; B Ambrosi; P Beck-Peccoz; R Elli; M Rondena; R Bara; G Weber
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

7.  Effect of dopamine receptor stimulation on the inhibition of LH pulsatility by a met-enkephaline (FK 33-824).

Authors:  E del Pozo; J Martin-Perez
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

8.  Prolactinoma in a middle-aged man with an osteoporotic fracture.

Authors:  S D Taylor; T M Kelly
Journal:  West J Med       Date:  1989-07

Review 9.  Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.

Authors:  S Franks
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

Review 10.  Effects of antihypertensive drugs on endocrine function.

Authors:  E P Brass
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.